TherapeuticsMD Inc (TXMD)
1.36
+0.03
(+2.26%)
USD |
NASDAQ |
Nov 22, 09:45
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 15.68M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -52.24% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 9.722 |
Price to Book Value | 0.5789 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.44% |
Profile
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories. |
URL | https://www.therapeuticsmd.com |
Investor Relations URL | http://ir.therapeuticsmd.com/ |
HQ State/Province | Florida |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Value |
Next Earnings Release | Mar. 05, 2025 (est.) |
Last Earnings Release | Nov. 12, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories. |
URL | https://www.therapeuticsmd.com |
Investor Relations URL | http://ir.therapeuticsmd.com/ |
HQ State/Province | Florida |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Value |
Next Earnings Release | Mar. 05, 2025 (est.) |
Last Earnings Release | Nov. 12, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |